HealthSkin Cancer Guidelines Add UNLOXCYT as Category 2A Option, Sun Pharma SaysBy Naomi CalderOct 21, 2026, 1:20 AM UTC
BusinessPeregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed GlioblastomaBy Nasdaq OMXSep 7, 2017, 12:10 PM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2017 and Recent DevelopmentsBy Nasdaq OMXMar 13, 2017, 8:05 PM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2017 and Recent DevelopmentsBy Nasdaq OMXDec 12, 2016, 9:05 PM UTC
BusinessNational Comprehensive Cancer Network (NCCN) Awards Three Grants for Combination Studies of Peregrine Pharmaceuticals’ Bavituximab in Multiple CancersBy Nasdaq OMXSep 6, 2016, 12:45 PM UTC
BusinessPeregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program in Lung, Breast and Other CancersBy Nasdaq OMXJan 11, 2016, 1:05 PM UTC
BusinessPeregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With BavituximabBy Nasdaq OMXJan 6, 2016, 1:05 PM UTC
